Literature DB >> 18172882

Regulatory T cells: what role do they play in antitumor immunity in patients with head and neck cancer?

Osama Alhamarneh1, Shoba M P Amarnath, Nicholas D Stafford, John Greenman.   

Abstract

Advances in the treatment modalities for head and neck squamous cell carcinoma (HNSCC) over the last 20 years involving surgery, radiotherapy, chemotherapy, and immunotherapy are not fully reflected in increases in the 5-year survival rates, mainly due to locoregional recurrences and to a lesser extent, distant metastasis. This can, in part, be attributed to the fact that HNSCC induces severe depression of a patient's immune system. Recent advances in understanding the complex host-tumor interactions have led to the identification of a distinct suppressor cell population known as regulatory T cells that play a crucial role in maintaining T-cell tolerance to self-antigens. Here, we present a critical review of our understanding of the involvement of regulatory T cells in controlling the T-cell immune response in tumor occurrence and progression in HNSCC with an emphasis on current and future immunotherapeutic approaches involving regulatory T cells.

Entities:  

Mesh:

Year:  2008        PMID: 18172882     DOI: 10.1002/hed.20739

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  25 in total

1.  Peripheral blood DNA methylation profiles are indicative of head and neck squamous cell carcinoma: an epigenome-wide association study.

Authors:  Scott M Langevin; Devin C Koestler; Brock C Christensen; Rondi A Butler; John K Wiencke; Heather H Nelson; E Andres Houseman; Carmen J Marsit; Karl T Kelsey
Journal:  Epigenetics       Date:  2012-03       Impact factor: 4.528

2.  Novel neoadjuvant immunotherapy regimen safety and survival in head and neck squamous cell cancer.

Authors:  Gregory T Wolf; Willard E Fee; Robert W Dolan; Jeffrey S Moyer; Michael J Kaplan; Paul M Spring; James Suen; Daniel E Kenady; Jason G Newman; William R Carroll; M Boyd Gillespie; Scott M Freeman; Lorraine Baltzer; Terry D Kirkley; Harvey J Brandwein; John W Hadden
Journal:  Head Neck       Date:  2011-01-31       Impact factor: 3.147

Review 3.  Emerging drugs for head and neck cancer.

Authors:  Yihui Wen; Jennifer R Grandis
Journal:  Expert Opin Emerg Drugs       Date:  2015-03-31       Impact factor: 4.191

4.  Tumor growth limited to subcutaneous site vs tumor growth in pulmonary site exhibit differential effects on systemic immunities.

Authors:  Junko Masuda; Eiji Takayama; Warren Strober; Ayano Satoh; Yuji Morimoto; Yasuko Honjo; Tatsuo Ichinohe; Shin-Ichi Tokuno; Toshiaki Ishizuka; Takahiro Nakata; Akifumi Mizutani; Naoki Umemura; Atsushi Kitani; Ivan J Fuss; Tsukasa Shigehiro; Harumi Kawaki; Masako Mizuno-Kamiya; Nobuo Kondoh; Masaharu Seno
Journal:  Oncol Rep       Date:  2017-05-17       Impact factor: 3.906

5.  Correlation of cellular immunity with human papillomavirus 16 status and outcome in patients with advanced oropharyngeal cancer.

Authors:  Derrick Wansom; Emily Light; Frank Worden; Mark Prince; Susan Urba; Douglas B Chepeha; Kitrina Cordell; Avraham Eisbruch; Jeremy Taylor; Nisha D'Silva; Jeffrey Moyer; Carol R Bradford; David Kurnit; Bhavna Kumar; Thomas E Carey; Gregory T Wolf
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2010-12

Review 6.  Immunology and Immunotherapy of Head and Neck Cancer.

Authors:  Robert L Ferris
Journal:  J Clin Oncol       Date:  2015-09-08       Impact factor: 44.544

7.  IL-35 expression is increased in laryngeal squamous cell carcinoma and in the peripheral blood of patients.

Authors:  Wei Wu; Hua Jiang; Ying Li; Mao-Xiao Yan
Journal:  Oncol Lett       Date:  2017-03-14       Impact factor: 2.967

8.  Peripheral blood immune cell methylation profiles are associated with nonhematopoietic cancers.

Authors:  Devin C Koestler; Carmen J Marsit; Brock C Christensen; William Accomando; Scott M Langevin; E Andres Houseman; Heather H Nelson; Margaret R Karagas; John K Wiencke; Karl T Kelsey
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-06-19       Impact factor: 4.254

9.  LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma.

Authors:  Wei-Wei Deng; Liang Mao; Guang-Tao Yu; Lin-Lin Bu; Si-Rui Ma; Bing Liu; J Silvio Gutkind; Ashok B Kulkarni; Wen-Feng Zhang; Zhi-Jun Sun
Journal:  Oncoimmunology       Date:  2016-10-07       Impact factor: 8.110

10.  Immunotherapy of head and neck cancer: current and future considerations.

Authors:  Alexander D Rapidis; Gregory T Wolf
Journal:  J Oncol       Date:  2009-08-09       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.